-+ 0.00%
-+ 0.00%
-+ 0.00%

Huiyu Pharmaceutical (688553.SH): Injectable parecoxib sodium and zoledronic acid injections obtained overseas marketing approval

Zhitongcaijing·08/10/2026 09:41:07
Listen to the news

Zhitong Finance App News, Huiyu Pharmaceutical (688553.SH) announced that the company's subsidiary Seacross (Europe) Pharma Ltd. recently received marketing licenses for injectable parecoxib sodium and zoledronic acid injections from the German Federal Agency for Drugs and Medical Devices, the Dutch Health Products Regulatory Authority, and the Spanish Medicines and Medical Devices Administration, respectively.

According to reports, injectable parecoxib sodium is a common preparation used to treat short-term pain after surgery in adults. Zoledronic acid injections are mainly used to prevent bone-related events (pathological fractures, spinal cord compression, bone lesions requiring radiotherapy or surgery, or hypercalcemia caused by tumors) in adult patients with advanced malignant tumors and to treat hypercalcemia (TIH) caused by adult tumors.